Inovio stock tumbles 25% on $75M share offering

Inovio Pharmaceuticals Inc (NASDAQ:INO) shares fell 25% Friday following the company's announcement that it priced a $75 million public offering at $1.05 per share.

The biotechnology company announced the pricing of an underwritten public offering of 58,747,235 shares of common stock at $1.05 per share and pre-funded warrants to purchase 12,681,337 shares at $1.049 per warrant, before underwriting discounts and commissions.

Inovio granted underwriters a 30-day option to purchase up to 10,714,285 additional shares at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about November 9, 2026, subject to customary closing conditions.

The gross proceeds from the offering, before deducting underwriting discounts, commissions and offering expenses, are expected to be approximately $75 million, excluding any exercise of the underwriter's option.

Jefferies and Piper Sandler are acting as joint book-running managers for the offering, while H.C. Wainwright & Co. is serving as lead manager.

Inovio focuses on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases. The company previously announced that its third quarter 2026 financial results will be released after the market close on November 10, 2026.